Latest news with #FRCPC
Yahoo
10-03-2025
- Health
- Yahoo
Women With This Condition May Be at Higher Risk of Dementia, According to Study
In case women and people assigned female at birth didn't have enough problems, a study revealed that some of us may be at higher risk for dementia than others—and that's a portion of us who are already suffering from severe symptoms of another condition. And, unfortunately, this is already on top of women already being at three times higher risk of Alzheimer's disease than men. What is the newly discovered risk factor and how can you protect yourself? 🩺 SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week 💊 A new study reveals that women and people assigned female at birth who have more severe perimenopause symptoms are more likely to have poor cognitive function and behavioral problems as they age. Researchers from the University of Calgary studied 896 women who identified as menopausal with an average age of 64, asking the women to recall and list perimenopausal symptoms and incidences they experienced. These included chills, forgetfulness, hot flashes, inattentiveness, irregular periods, mood swings, night sweats, sleep disruptions, slowed metabolism, vaginal dryness and weight gain, plus other unnamed symptoms. Women who experienced more and more severe menopausal symptoms displayed a higher likelihood of "mild behavioral impairment symptoms" later in life, as well as higher rates of cognitive impairment. Related: If you've been having hot flashes for a while, here's some good news: There's no need to panic just yet. "Greater menopausal symptom burden may be associated with greater cognitive and behavioral decline in later life, both risk markers of dementia," study author Dr. Zahinoor Ismail, MD, FRCPC, wrote. All that said, the study's authors acknowledge that a lot more research still needs to be done, and likely for longer periods of time on larger sample sizes. What's more, researchers also plan to do more intense studying of other potential confounding factors in subjects to draw more direct correlations and possible causations. These factors can include surgeries, other co-occurring health conditions, genetic factors and family history. Related: Dr. Ismail also notes that estrogen therapy (often also called hormone replacement therapy) can be a big help with perimenopause and menopause symptoms, so if nothing else, you can at least feel better now. Talk to your doctor about hormone replacement therapy if you haven't. Other menopause treatments vary by symptom, but rest assured, there is help out there for you! Whether it's hot flashes, sleep problems, hormonal changes or weight gain, talk to your doctor about your needs and your options—and make sure you also discuss ways to protect your brain health, too. Up Next:
Associated Press
10-03-2025
- Business
- Associated Press
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors. ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS 'ON' (active) state of greater than 90% of all KRAS mutations and to provide complete target coverage in tumors. These properties have the potential to translate into best-in-class safety and efficacy. KRAS driver mutations are found in greater than 20% of all patients with metastatic cancer, with the majority in non-small cell lung cancer (NSCLC), pancreatic ductal carcinoma (PDAC), and colorectal cancer (CRC). 'With this trial, we hope to bring a breakthrough therapy to the many patients with KRAS-driven cancers who are still underserved,' said Andrew Chi, M.D., Ph.D., Chief Medical Officer of Alterome. 'We have shown in preclinical studies that ALTA3263 has the attributes to potentially address this significant unmet need and transform patient outcomes.' 'While progress has been made in KRAS mutant cancers, we still regularly see patients who have exhausted all available effective treatment options and also suffer from toxic side effects of current therapies,' said Anthony Tolcher, M.D., FRCPC, Founder of NEXT Oncology and primary investigator on the ALTA3263 Phase 1/1b trial. 'We are excited to participate in this trial, and hope that ALTA3263 will usher in the next generation of KRAS targeted therapies that promise greater efficacy and improved tolerability and safety for patients.' The Phase 1/1b, open-label, dose-escalation and multiple cohort study is evaluating the safety, tolerability, pharmacokinetics, and preliminary clinical activity of ALTA3263 in adults with advanced unresectable or metastatic solid tumors with KRAS mutations (NCT06835569). About ALTA3263 ALTA3263 is a non-covalent, orally bioavailable, highly potent KRAS isoform-selective dual ON/OFF state inhibitor designed to target >90% of all KRAS driver mutations in cancer. While mutation-specific KRAS inhibitors that target the KRAS OFF-state have demonstrated clinical benefit, highly prevalent KRAS mutations such as G12D and G12V exist predominantly in the ON-state and remain a substantial unmet medical need. ALTA3263 inhibits KRAS with picomolar to low single-digit nanomolar potency and targets both the ON and OFF states while exhibiting high selectivity for KRAS over HRAS and NRAS to allow for a favorable therapeutic index. These properties, together with excellent pharmacokinetic and tolerability profiles enable complete and continuous target coverage to inhibit KRAS-driven cancers. ALTA3263 led to deep regressions in multiple KRAS mutant preclinical models while being well-tolerated during prolonged oral dosing. These data were presented in an oral presentation at the 2024 EORTC-NCI-AACR (ENA) Symposium. For more information on ALTA3263, visit Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a potential best-in-class, KRAS-selective (ON/OFF) inhibitor for KRAS-driven cancers. Alterome has raised more than $231 million in venture capital to date and is led by a team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs. Scott Moorefield Alterome Therapeutics [email protected]: Michael Galfetti SOURCE: Alterome Therapeutics, Inc. Copyright Business Wire 2025. PUB: 03/10/2025 07:30 AM/DISC: 03/10/2025 07:30 AM
Los Angeles Times
13-02-2025
- Health
- Los Angeles Times
Children's Hospital Los Angeles Opens New Cardiac Imaging Suite
First Pediatric Hospital in the United States to Feature Low-Field MRI Technology Children's Hospital Los Angeles has opened its new Cardiac Imaging Suite, a 6,650-square-foot facility that will improve access, service and quality of care for cardiac patients featuring state-of-the-art technology that cannot be found at any other pediatric center in the United States. The suite houses the new, FDA-approved Siemens FreeMax 0.55 Tesla MRI system, a first-in-the-nation machine for pediatrics, that will allow for new ways to image children's hearts, lungs and more. 'Children's Hospital Los Angeles is committed to pioneering the latest research and innovations in the pursuit of advancing the standards of pediatric care. It's a commitment we take seriously as one of the top pediatric cardiology and heart surgery programs in the country that routinely treats some of the most complex cardiac patients,' said Paul F. Kantor, MBBCh, MSc, FRCPC, chief of the Division of Cardiology and co-director of the Heart Institute at Children's Hospital Los Angeles. 'We are thrilled to be the first in the U.S. offering this groundbreaking new technology to children and could not be more excited to harness this machine to further research and develop new applications in pediatric and fetal imaging.' Low-field MRI offers diagnostic-quality images of the heart in a quieter, much more spacious environment with a magnet that is three to six times lower in strength than today's conventional clinical systems, making it safer and more comfortable for children. While stronger magnets provide a stronger signal, any movement or air can cause distortion in the image. The low-field MRI has a weaker signal and can accommodate motion, making it ideal for imaging fetuses, the heart, lungs and GI tract. In addition, because the patient does not need to be perfectly still, low-field MRI will reduce the need for general anesthesia in children as young as four or five years old; alternative methods of pain management with fewer side effects and preoperative restrictions can be used instead, such as virtual reality goggles. Low-field MRI is also excellent for patients who have metal implants, such as pacemakers or have a larger body size, which can make it difficult to get good ultrasound or computed tomography images. 'Low-field MRI opens up a world of possibilities that can improve care for children, including the development of real-time imaging capabilities,' said John Wood, MD, PhD, director of Cardiovascular MRI at Children's Hospital Los Angeles. 'This technology will allow Children's Hospital Los Angeles to pioneer novel MRI applications, such as using the 0.55T magnet to guide procedures, such as cardiac catheterizations. Using low-field MRI instead of X-ray would be a big deal for children, as limiting radiation exposure is key. The applications for lung imaging are also exciting, as there is no good way currently to monitor the progression of lung disease in babies and children. While it will take time to develop these techniques and translate them to the clinical environment, that is where we are headed thanks to this revolutionary machine.' An international MRI expert, Dr. Wood and his team were the first in the world to perform real-time imaging of a human fetal heart – without the need for cardiac synchronization – using low-field MRI. The Cardiac Imaging Suite also features the Siemens Sola 1.5 Tesla MRI machine, five patient prep and recovery bays, an anesthesia induction room and space for a future cardiac CT scanner. The 1.5T magnet is the current gold standard for advanced cardiac MRI and delivers exceptional image clarity, ensuring high-resolution imaging and faster scan times. The suite also offers specialized stress testing for myocardial perfusion, addressing blood flow issues in the heart. Children's Hospital Los Angeles is the only facility in California providing this advanced diagnostic service, setting a new standard for pediatric cardiac imaging.
